CNTA CENTESSA PHARMACEUTICALS PLC Product Launches 8-K Filing 2024 - Positive Clinical Data Centessa Pharmaceuticals announced positive interim Phase 1 clinical data for its orexin agonist, ORX750, showing significant improvements in wakefulness and sleep latency in sleep-deprived volunteers, with favorable safety results.Get access to all SEC 8-K filings of the CENTESSA PHARMACEUTICALS PLC